Actively Recruiting
Study of XB010 in Subjects With Solid Tumors
Led by Exelixis · Updated on 2026-04-15
396
Participants Needed
19
Research Sites
167 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
CONDITIONS
Official Title
Study of XB010 in Subjects With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older on the day of consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- Adequate organ and marrow function.
- Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.
- For Cohort Expansion: subjects with non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell cancer, or triple-negative breast cancer.
- Ability to understand and comply with protocol requirements and signing informed consent.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Exelixis Clinical Site #4
Irvine, California, United States, 92618
Actively Recruiting
2
Exelixis Clinical Site #19
Los Angeles, California, United States, 90095
Actively Recruiting
3
Exelixis Clinical Site #10
Washington D.C., District of Columbia, United States, 20007
Actively Recruiting
4
Exelixis Clinical Site #18
Orlando, Florida, United States, 32827
Actively Recruiting
5
Exelixis Clinical Site #12
Atlanta, Georgia, United States, 30322
Actively Recruiting
6
Exelixis Clinical Site #15
Chicago, Illinois, United States, 60637
Actively Recruiting
7
Exelixis Clinical Site #5
St Louis, Missouri, United States, 63110
Actively Recruiting
8
Exelixis Clinical Site #3
Huntersville, North Carolina, United States, 28078
Actively Recruiting
9
Exelixis Clinical Site #6
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
10
Exelixis Clinical Site #9
Nashville, Tennessee, United States, 37203
Actively Recruiting
11
Exelixis Clinical Site #1
Austin, Texas, United States, 78758
Actively Recruiting
12
Exelixis Clinical Site #7
Dallas, Texas, United States, 74246
Actively Recruiting
13
Exelixis Clinical Site #8
Houston, Texas, United States, 77030
Actively Recruiting
14
Exelixis Clinical Site #11
Fairfax, Virginia, United States, 22031
Actively Recruiting
15
Exelixis Clinical Site #2
Fairfax, Virginia, United States, 22031
Actively Recruiting
16
Exelixis Clinical Site #17
Leicester, England, United Kingdom, LE1 5WW
Actively Recruiting
17
Exelixis Clinical Site #13
London, England, United Kingdom, W1G 6AD
Actively Recruiting
18
Exelixis Clinical Site #16
London, England, United Kingdom, W1T 7HA
Actively Recruiting
19
Exelixis Clinical Site #14
Manchester, England, United Kingdom, M20 4BX
Actively Recruiting
Research Team
E
Exelixis Clinical Trials
CONTACT
B
Backup or International
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here